Pfizer explores sale of hospital drugs unit, sources say
Exclusive: Pfizer explores sale of hospital drugs unit, sources say
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.
Pfizer (PFE) has been on a downward spiral lately with significant selling pressure. After declining 11% over the past four ...
After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, Reuters’ ...
Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...
Keurig Dr Pepper brings in Drew Panayiotou to accelerate digital marketing and Andrew Springate takes a new role.
Hosted on MSN1d
Should Value Investors Buy Pfizer (PFE) Stock?One company value investors might notice is Pfizer (PFE). PFE is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 9.16, which compares to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback